65,437 trials
Autosomal Dominant Polycystic Kidney Disease
Primary: Total Kidney Volume — 1500.5; 1573.1; 1567.9; 1729.4 mL
Dental Implant
Primary: Implant Stability Scale (ISQ) Score Change After 16 Weeks — 73; 71; 69; 78 units on a scale — p=>0.05
Urethral Analgesia
Primary: Voiding Efficiency — 87; 90 Percent voiding efficiency
Intubation; Difficult
Primary: Number of Attempts for I-gel or Classic-LMA Insertions — 25; 22; 2; 5 attempt — p=0.5033
Multiple Myeloma
Primary: The Number of Patients That Achieve Complete Response — 7 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13 — -1.55 Units on a scale
Validation Studies
Primary: delta13C Added Sugar Biomarker — -19.66; -19.64 ‰ δ13C — p=<0.001
Non-hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Bortezomib — 1.5; 1.0 mg/m²
Aortic Valve Stenosis
Primary: Acute Delivery System Success — 95.0 percentage of participants
Seizures
Primary: Percentage of Participants With Adverse Events — 88.9; 92.3; 88.2; 90.4 Percentage of participants
Atrial Fibrillation · Stroke
Primary: Primary Safety Endpoint (Device Group Only) — 6 Participants
Exudative Macular Degeneration
Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001
Carcinoma, Small Cell · Small Cell Lung Cancer
Primary: Objective Response Rate — 3 Participants
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001
Clostridium Difficile
Primary: Number of Subjects With CDI Recurrence — 26; 16 participants